What is ANRO's health score?

Alto Neuroscience, Inc. (ANRO) has a TradeApes health score of 42 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ANRO's estimated fair value?

Based on our 5-year discounted cash flow model, Alto Neuroscience, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ANRO undervalued or overvalued?

Our model currently rates ANRO as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ANRO... Refresh in a moment for the full analysis.

Alto Neuroscience, Inc. (ANRO)

Healthcare Inconclusive inconclusive weak

$18.26

Updated: 2026-06-06

TradeApes Score

Financial Strength

20 Stressed

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

60 Healthy

Risk

80 Strong

Key Findings

+ Active debt paydown — total debt declining more than 10% year over year

Unlock Full Report →

− High leverage — net debt/EBITDA between 3× and 5×

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.